ICH S7B In Vitro Assays Do Not Address Mechanisms of QT C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT C Studies
Clinical Pharmacology & Therapeutics · 2023
DOI: 10.1002/cpt.3047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Wendy W Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US…. Hauptthemen laut MEDLINE: Long QT Syndrome, Torsades de Pointes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Current cardiac safety testing focuses on detecting drug‐induced QT C prolongation as a surrogate for risk of Torsade de Pointes. The nonclinical strategy, described in International Conference on Harmonization (ICH) S7B, includes in vitro assessment of hERG block or ventricular repolarization delay and in vivo QT prolongation. Several studies have reported predictive values of ICH S7B results for clinical QT C outcomes for small molecules; none has examined peptides and proteins other than monoclonal antibodies. To address this knowledge gap, information for peptides and proteins submitted to the US Food and Drug Administration (FDA) was collected. Results of hERG assays, ventricular repolarization assays, and in vivo QT assessment were compared with clinical QT C study outcomes. The results show that 14% clinical QT C studies for approved and investigational products failed to exclude 10‐ms QT C prolongation. Clinical QT C prolongation for these molecules lacked concentration‐dependence which is expected for hERG block‐mediated mechanism or QT C prolongation could not be excluded due to characterization in the clinical study. The hERG and ventricular repolarization assays do not identify clinical QT C prolongation potential for peptides and proteins. Lack of alignment between hERG and ventricular repolarization assay results and clinical QT C outcomes suggests that the mechanisms of QT C prolongation by some peptides and proteins are unrelated to direct cardiac ion channel block. Similar to large targeted proteins and monoclonal antibodies, peptides and proteins regardless of size have a low likelihood of direct cardiac ion channel interactions. This characteristic supports waiving the requirement for thorough QT assessment for products comprised of naturally occurring amino acids unless proarrhythmia potential is suggested by nonclinical or clinical data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Division of Hematology, Oncology, Toxicology, Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryla…
- Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland…
- Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
ORCID-Profile: Wendy W Wu, Jose Vicente, David G Strauss
Zitieren
APA
Wu, W. W., Choe, M., Johannesen, L., Vicente, J., Bende, G., Stockbridge, N. L., Strauss, D. G., & Garnett, C. (2023). ICH S7B In Vitro Assays Do Not Address Mechanisms of QT C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT C Studies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3047
Vancouver
Wu WW, Choe M, Johannesen L, Vicente J, Bende G, Stockbridge NL, et al. ICH S7B In Vitro Assays Do Not Address Mechanisms of QT C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT C Studies. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3047
BibTeX
@article{Wu2023,
author = {Wu, Wendy W and Choe, Moran and Johannesen, Lars and Vicente, Jose and Bende, Girish and Stockbridge, Norman L and Strauss, David G and Garnett, Christine},
title = {ICH S7B In Vitro Assays Do Not Address Mechanisms of QT C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT C Studies},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
doi = {10.1002/cpt.3047}
}
EUVIMED